Granules India Limited has informed the Exchange about Transcript
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Granules India filed the transcript of its Q1 FY26 earnings call held on August 12, 2025. Q1 revenue grew 3% year-on-year to Rs. 12,101 million, including Rs. 291 million from newly acquired Senn Chemicals AG. Gross margin improved 593 bps YoY to 64.9%, but EBITDA margin fell 159 bps to 20.4% due to higher professional expenses for US FDA remediation and manpower costs from the Senn Chemicals consolidation. Net debt rose to Rs. 9,480 million post the Senn acquisition (from Rs. 7,061 million in Q4 FY25). Management said Gagillapur FDA remediation is in final stages, with a meeting planned in September and potential re-inspection by December 2025. The new Genome Valley (GLS) facility cleared its first US FDA pre-approval inspection with a single observation, unlocking 10 billion doses of additional capacity (40% increase). Management guided FY27 as a strong growth year once Gagillapur and GLS approvals come through. The peptide/CDMO platform through Senn Chemicals (acquired for ~Rs. 450 crores) and new subsidiary Ascelis Peptides was highlighted as a long-term growth engine, with a peptides R&D centre at IIT Hyderabad expected operational by October 2025.
Near-term, margin pressure from remediation costs and Senn integration may persist, and the stock could stay range-bound until Gagillapur FDA clearance materializes. However, expanded capacity, new product approvals, and the peptide CDMO platform provide clear medium-term growth visibility, supporting a constructive longer-term outlook for shareholders.